ECSP045345A - Tratamiento de la gastroparesia - Google Patents
Tratamiento de la gastroparesiaInfo
- Publication number
- ECSP045345A ECSP045345A EC2004005345A ECSP045345A ECSP045345A EC SP045345 A ECSP045345 A EC SP045345A EC 2004005345 A EC2004005345 A EC 2004005345A EC SP045345 A ECSP045345 A EC SP045345A EC SP045345 A ECSP045345 A EC SP045345A
- Authority
- EC
- Ecuador
- Prior art keywords
- gastroparesia
- treatment
- glp
- patients
- compounds
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 2
- 230000030136 gastric emptying Effects 0.000 abstract 2
- 208000001288 gastroparesis Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37165002P | 2002-04-10 | 2002-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045345A true ECSP045345A (es) | 2006-04-19 |
Family
ID=29250714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005345A ECSP045345A (es) | 2002-04-10 | 2004-10-08 | Tratamiento de la gastroparesia |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050164925A1 (https=) |
| EP (1) | EP1496924A4 (https=) |
| JP (1) | JP2005530732A (https=) |
| KR (1) | KR20040098063A (https=) |
| CN (1) | CN1735423A (https=) |
| AU (1) | AU2003220403A1 (https=) |
| BR (1) | BR0308904A (https=) |
| CA (1) | CA2480858A1 (https=) |
| EA (1) | EA200401345A1 (https=) |
| EC (1) | ECSP045345A (https=) |
| HR (1) | HRP20040939A2 (https=) |
| IL (1) | IL164266A0 (https=) |
| MX (1) | MXPA04009929A (https=) |
| NO (1) | NO20044815L (https=) |
| NZ (1) | NZ535684A (https=) |
| PL (1) | PL373658A1 (https=) |
| WO (1) | WO2003087139A2 (https=) |
| ZA (1) | ZA200408111B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| JP2007537981A (ja) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| EP1793891B1 (en) | 2004-08-18 | 2011-11-09 | Metacure Limited | Monitoring, analysis, and regulation of eating habits |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| WO2006087712A2 (en) | 2005-02-17 | 2006-08-24 | Metacure N.V. | Charger with data transfer capabilities |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| US8265758B2 (en) * | 2005-03-24 | 2012-09-11 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
| WO2007080595A2 (en) | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
| WO2006129321A2 (en) | 2005-06-02 | 2006-12-07 | Metacure N.V. | Gi lead implantation |
| US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
| US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
| ES2495741T3 (es) * | 2006-04-20 | 2014-09-17 | Amgen, Inc | Compuestos de GLP-1 |
| AU2012203915B9 (en) * | 2006-04-20 | 2014-10-09 | Amgen Inc. | GLP-1 compounds |
| US8417329B2 (en) * | 2007-05-09 | 2013-04-09 | Metacure Ltd. | Analysis and regulation of food intake |
| US8423130B2 (en) * | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| EP2482840A4 (en) * | 2009-08-07 | 2013-06-26 | Mannkind Corp | VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| WO2011136361A1 (ja) | 2010-04-30 | 2011-11-03 | 株式会社 三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US5981488A (en) * | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
-
2003
- 2003-03-27 IL IL16426603A patent/IL164266A0/xx unknown
- 2003-03-27 KR KR10-2004-7016025A patent/KR20040098063A/ko not_active Ceased
- 2003-03-27 HR HRP20040939 patent/HRP20040939A2/hr not_active Application Discontinuation
- 2003-03-27 MX MXPA04009929A patent/MXPA04009929A/es not_active Application Discontinuation
- 2003-03-27 JP JP2003584094A patent/JP2005530732A/ja active Pending
- 2003-03-27 US US10/508,762 patent/US20050164925A1/en not_active Abandoned
- 2003-03-27 CA CA002480858A patent/CA2480858A1/en not_active Abandoned
- 2003-03-27 EA EA200401345A patent/EA200401345A1/ru unknown
- 2003-03-27 EP EP03716707A patent/EP1496924A4/en not_active Withdrawn
- 2003-03-27 BR BR0308904-5A patent/BR0308904A/pt not_active IP Right Cessation
- 2003-03-27 NZ NZ535684A patent/NZ535684A/xx unknown
- 2003-03-27 PL PL03373658A patent/PL373658A1/xx unknown
- 2003-03-27 WO PCT/US2003/008457 patent/WO2003087139A2/en not_active Ceased
- 2003-03-27 AU AU2003220403A patent/AU2003220403A1/en not_active Abandoned
- 2003-03-27 CN CNA038080079A patent/CN1735423A/zh active Pending
-
2004
- 2004-10-07 ZA ZA200408111A patent/ZA200408111B/xx unknown
- 2004-10-08 EC EC2004005345A patent/ECSP045345A/es unknown
- 2004-11-05 NO NO20044815A patent/NO20044815L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200401345A1 (ru) | 2005-08-25 |
| WO2003087139A2 (en) | 2003-10-23 |
| EP1496924A2 (en) | 2005-01-19 |
| JP2005530732A (ja) | 2005-10-13 |
| NZ535684A (en) | 2006-03-31 |
| AU2003220403A1 (en) | 2003-10-27 |
| KR20040098063A (ko) | 2004-11-18 |
| BR0308904A (pt) | 2005-05-03 |
| MXPA04009929A (es) | 2006-03-10 |
| CN1735423A (zh) | 2006-02-15 |
| WO2003087139A3 (en) | 2004-01-08 |
| NO20044815L (no) | 2005-01-07 |
| US20050164925A1 (en) | 2005-07-28 |
| PL373658A1 (en) | 2005-09-05 |
| CA2480858A1 (en) | 2003-10-23 |
| EP1496924A4 (en) | 2007-05-30 |
| IL164266A0 (en) | 2005-12-18 |
| HRP20040939A2 (en) | 2004-12-31 |
| ZA200408111B (en) | 2005-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045345A (es) | Tratamiento de la gastroparesia | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| MX2022001137A (es) | Compuestos agonistas de gipr. | |
| PA8534601A1 (es) | Activadores de glucocinasa del tipo isoindolin-1-ona | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| NO20071604L (no) | Loxapinanaloger og fremgangsmater for anvendelse derav. | |
| UY28314A1 (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| EP1490044A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS | |
| MX2008002293A (es) | Uso novedoso de compuestos peptidicos para tratar dolor muscular. | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| ECSP034810A (es) | Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6 | |
| IS8485A (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BRPI0511995A (pt) | uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal | |
| BRPI0512622A (pt) | uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor | |
| DE60026146D1 (de) | Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction | |
| UY27244A1 (es) | Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple | |
| CL2007002387A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor. | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| BR0209541A (pt) | Uso das imidazotriazinonas 2-fenil-substituìdas | |
| MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
| PT1030667E (pt) | Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono | |
| DK1532131T3 (da) | Motilid-forbindelser | |
| NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
| EP1569634B8 (en) | Use of a ppar-alpha agonist and metformin for the treatment of obesity |